Table 2.
Comparison of clinical outcomes of different nutritional support therapies in patients with COVID-19.
| EN group(n=48) | PN group(n=23) | P-value | |
|---|---|---|---|
| Therapeutic management of COVID-19 | |||
| Antibiotics (n, %) | 33(68.8) | 20(87.0) | 0.099 |
| Dexamethasone (n, %) | 18(37.5) | 11(47.8) | 0.407 |
| Intravenous immunoglobulins (n, %) | 22(45.8) | 12(52.2) | 0.617 |
| Complications during hospitalization (n, %) | 5(10.4) | 16(69.6) | <0.001 |
| Outcomes | |||
| Respiratory failure (n, %) | 5(10.4) | 13(56.5) | <0.001 |
| Shock (n, %) | 0(0.0) | 11(47.8) | <0.001 |
| Organ failure (n, %) | 1(2.1) | 13(56.5) | <0.001 |
| Use vasopressors (n, %) | 0(0.0) | 12(52.2) | <0.001 |
| Intensive care unit admission (n, %) | 0(0.0) | 11(47.8) | <0.001 |
| 60-day mortality | 1(2.1) | 7(30.4) | 0.001 |
The meaning of the values in bold is the P-value is less than 0.05.